Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS ‐MI): rationale and design

ConclusionsEMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI.

Source: ESC Heart Failure - May 8, 2024 Category: Cardiology Authors: Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, Katriona Brooksbank, Ross T. Campbell, Richard Good, Pardeep S. Jhund, Peter Kellman, Ninian N. Lang, Kenneth Mangion, Patrick B. Mark, Alex McConnachie, John J.V. McMurray, Barbara Meyer, V Tags: Study Design Source Type: research